COVID-19

News

AbbVie begins trials of COVID-19 antibody therapy

AbbVie is to begin clinical development of an antibody designed to neutralise the SARS-CoV-2 coronavirus after licensing the therapy in from Harbour BioMed and Utrecht University.<

Views & Analysis

ABPI chief exec on the UK industry’s learnings from COVID-19

The ABPI’s chief executive Dr Richard Torbett shares his views on how the industry has adapted to COVID-19 and explains why the post-pandemic future is looking bright for the UK industry.

News

Family doctors begin COVID-19 immunisation drive in UK

The roll-out of the biggest vaccination programme in the history of the UK’s NHS is gathering pace, as family doctors and their teams begin taking delivery of Pfizer/BioNTech’s COVID-19 sho

News

Novartis/Incyte draw blank with Jakafi in COVID-19

Novartis/Incyte’s Jakafi (ruxolitinib) looks unlikely to be added to the list of therapies that can be used against COVID-19, after it failed to cut complications or death in a phase 3 tria

Views & Analysis

Deep Dive: Patients and Partnerships

As this issue’s title suggests, patient centricity is about more than just talking points and marketing strategies – it requires companies to truly listen to, engage with and partner with t

News

Sanofi/GSK trial woes delay a billion COVID-19 shots by nine...

Sanofi and GlaxoSmithKline have said their COVID-19 vaccine has hit a snag in clinical development, prompting analysts to note this could delay delivery of potentially more than a billion s

AbbVie begins trials of COVID-19 antibody therapy

ABPI chief exec on the UK industry’s learnings from COVID-19

Family doctors begin COVID-19 immunisation drive in UK

Novartis/Incyte draw blank with Jakafi in COVID-19

Deep Dive: Patients and Partnerships

Sanofi/GSK trial woes delay a billion COVID-19 shots by nine...

Scribe Therapeutics joins the IPO queue

Discover a new era of healthcare panel engagement: Grounded ...

COVID-19

Editor's Picks